BLU-667 Targets RET-Altered Cancers [News in Brief]

Findings from a phase I study indicate that the investigational RET inhibitor BLU-667 is safe and well tolerated, inducing good responses in patients with RET-altered medullary thyroid cancer or non–small cell lung cancer.

https://ift.tt/2xy0NCt